Corient Private Wealth LLC Cuts Stock Position in Pfizer Inc. $PFE

Corient Private Wealth LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 2.9% in the 4th quarter, HoldingsChannel reports. The firm owned 2,829,723 shares of the biopharmaceutical company’s stock after selling 84,712 shares during the quarter. Corient Private Wealth LLC’s holdings in Pfizer were worth $70,487,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Pfizer in the fourth quarter valued at $1,830,986,000. Morgan Stanley lifted its holdings in Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after buying an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Pfizer by 47.8% during the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock worth $638,787,000 after acquiring an additional 8,108,887 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Pfizer by 577.5% in the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after acquiring an additional 7,489,189 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PFE shares. Morgan Stanley raised their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. UBS Group reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Citigroup raised their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a research report on Monday, March 2nd. Finally, Wolfe Research restated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.82.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reaffirmed its 2026 guidance and said its strategic outlook remains intact, which should help limit downside if investors focus on fundamentals rather than the management change. Pfizer stock slides following CFO exit, 2026 guidance reaffirmed
• Positive Sentiment: The company moved quickly to appoint an interim finance chief, suggesting Pfizer has a planned transition process in place rather than a broader disruption to operations. Pfizer Announces Chief Financial Officer Transition
• Neutral Sentiment: News coverage also noted that Pfizer’s recent move is part of a broader investor debate about the company’s near-term growth catalysts and pipeline execution, rather than a change to its core business outlook. Reuters coverage of CFO departure
• Negative Sentiment: The biggest overhang is the unexpected departure of the CFO, which can create uncertainty about financial discipline and near-term investor confidence, helping explain why PFE has been declining. Pfizer CFO to leave company for consumer goods role

Pfizer Stock Up 0.2%

Pfizer stock opened at $25.25 on Friday. The company has a market capitalization of $143.94 billion, a P/E ratio of 19.28 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The stock has a 50-day simple moving average of $26.22 and a 200-day simple moving average of $26.33.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the business posted $0.92 EPS. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 12th. Stockholders of record on Friday, May 8th were given a dividend of $0.43 per share. The ex-dividend date was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.